论文部分内容阅读
目的:观察左西孟旦对急性心力衰竭患者心功能及cTnT、hs-CRP、NT-proBNP水平影响。方法:选取在我院就诊的327例急性心力衰竭患者,按照治疗方式不同,分为观察组(常规治疗+左西孟旦)164例和对照组(常规治疗)163例,对比两组用药前及用药后24 h的左心射血分数(LVEF)、每搏输出量(SV)、肌钙蛋白T(cTnT)、超敏C反应蛋白(hs-CRP)和氨基末端B型利钠肽前体(NT-proBNP)水平。结果:治疗前,两组LVEF和SV比较,差异无统计学意义(P>0.05)。治疗后观察组LVEF和SV均显著高于治疗前(P<0.05);对照组LVEF显著高于治疗前(P<0.05),SV与治疗前比较,差异无统计学意义(P>0.05)。治疗后观察组LVEF和SV均显著高于对照组(P<0.05)。治疗前两组cTnT、hs-CRP、NT-proBNP水平比较,差异无统计学意义(P>0.05)。治疗后两组cTnT、hs-CRP、NT-proBNP水平均显著低于治疗前(P<0.05)。治疗后观察组cTnT、hs-CRP、NT-proBNP水平显著低于对照组(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。结论:左西孟旦治疗急性心力衰竭可明显增加心肌收缩力,抑制心肌重塑,减轻炎症反应,改善患者预后。
Objective: To observe the effect of levosimendan on cardiac function, cTnT, hs-CRP and NT-proBNP levels in patients with acute heart failure. Methods: A total of 327 acute heart failure patients treated in our hospital were divided into observation group (conventional treatment + levosimendan) 164 cases and control group (conventional treatment) 163 cases. According to the different treatment methods, And left ventricular ejection fraction (LVEF), stroke volume (SV), cTnT, hs-CRP and amino-terminal B-type natriuretic peptide Body (NT-proBNP) levels. Results: Before treatment, there was no significant difference between LVEF and SV in the two groups (P> 0.05). The LVEF and SV of observation group after treatment were significantly higher than those before treatment (P <0.05). The LVEF of control group was significantly higher than that before treatment (P <0.05). There was no significant difference between SV and before treatment (P> 0.05). After treatment, LVEF and SV in the observation group were significantly higher than those in the control group (P <0.05). There was no significant difference in cTnT, hs-CRP and NT-proBNP levels between the two groups before treatment (P> 0.05). After treatment, the levels of cTnT, hs-CRP and NT-proBNP in both groups were significantly lower than those before treatment (P <0.05). After treatment, the levels of cTnT, hs-CRP and NT-proBNP in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: Levosimendan can improve myocardial contractility, inhibit myocardial remodeling, reduce inflammation and improve prognosis in patients with acute heart failure.